Hu, Ernst, Snelling, Ye, Paneni, Zelniker, Szabo, Pokreisz, Kiss, & Podesser (2026). Cardiovascular, limb, and kidney effects of SGLT2 inhibitors in patients with peripheral artery disease: a systematic review and meta-analysis of randomized controlled trial data.. Cardiovascular diabetology.
Hu, Ernst, Snelling, Ye, Paneni, Zelniker, et al. Cardiovascular, limb, and kidney effects of SGLT2 inhibitors in patients with peripheral artery disease: a systematic review and meta-analysis of randomized controlled trial data.. Cardiovascular diabetology. 2026; PMID: 42144626
Hu, Ernst, Snelling, et al. Cardiovascular, limb, and kidney effects of SGLT2 inhibitors in patients with peripheral artery disease: a systematic review and meta-analysis of randomized controlled trial data.[J]. Cardiovascular diabetology. 2026.
@article{hu2026,
author = {Hu and Ernst and Snelling and Ye and Paneni and Zelniker and Szabo and Pokreisz and Kiss and Podesser},
title = {Cardiovascular, limb, and kidney effects of SGLT2 inhibitors in patients with peripheral artery disease: a systematic review and meta-analysis of randomized controlled trial data.},
journal = {Cardiovascular diabetology},
year = {2026},
note = {PMID: 42144626},
}
TY - JOUR AU - Hu AU - Ernst AU - Snelling AU - Ye AU - Paneni AU - Zelniker AU - Szabo AU - Pokreisz AU - Kiss AU - Podesser TI - Cardiovascular, limb, and kidney effects of SGLT2 inhibitors in patients with peripheral artery disease: a systematic review and meta-analysis of randomized controlled trial data. T2 - Cardiovascular diabetology PY - 2026 AN - PMID:42144626 ER -
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) provide substantial cardiovascular benefits across a broad spectrum of patients at high atherosclerotic risk. However, evidence for their cardiovascular efficacy in patients with peripheral artery disease (PAD) remains limited. Accordingly, we conducted this systematic review and meta-analysis to synthesize available evidence and clarify the cardiovascular, limb, and kidney outcomes of SGLT2i in patients with PAD.